MS4A1 and non-Hodgkin lymphoma: The anti-CD20 monoclonal antibody rituximab is approved for the treatment of many diseases, including non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and rheumatoid arthritis [31].